Tvardi Therapeutics
TVRD
92 hedge funds and large institutions have $265M invested in Tvardi Therapeutics in 2015 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 41 increasing their positions, 18 reducing their positions, and 8 closing their positions.
213% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 8
128% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 18
123% more call options, than puts
Call options by funds: $507K | Put options by funds: $227K
81% more capital invested
Capital invested by funds: $146M → $265M (+$119M)
23% more funds holding
Funds holding: 75 → 92 (+17)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$51M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$19M |
| 3 |
Jennison Associates
New York
|
+$7.97M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$4.88M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSA
Wall Street Associates
Lajolla,
California
|
-$4.53M |
| 2 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$3.94M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.93M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.53M |
| 5 |
MCM
Moore Capital Management
New York
|
-$1.22M |
TVRD Hedge Fund Activity: Q3 2015 in Review
92 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2015, worth a combined $265M — up 81% from $146M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new TVRD positions and 8 closed out — a net gain of 17 holders — while 41 added to existing stakes and 18 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $51M. The largest seller was Wall Street Associates, cutting an estimated $4.53M.
- 92 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2015, up from 75 in Q2 2015.
- Funds reported $265M of Tvardi Therapeutics stock for Q3 2015, up 81% quarter-over-quarter.
- 25 funds opened new Tvardi Therapeutics positions in Q3 2015 and 8 closed out, a net change of +17 holders.
- The largest Tvardi Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $51M added.
- The largest Tvardi Therapeutics seller in Q3 2015 was Wall Street Associates, an estimated $4.53M sold.
Based on aggregated 13F filings for Q3 2015.